SAD/MAD Safety and PK Study of QPX9003 (Novel Polymyxin) in Normal Healthy Volunteers
Status:
Recruiting
Trial end date:
2022-03-22
Target enrollment:
Participant gender:
Summary
The worldwide spread of resistance to antibiotics among gram-negative bacteria, particularly
members of the ESKAPE group of pathogens, has resulted in a crisis in the treatment of
hospital acquired infections. In particular, the presence of multi-drug resistant
Acinetobacter baumannii and Pseudomonas aeruginosa in hospitals around the world poses a
considerable threat.
.
Phase:
Phase 1
Details
Lead Sponsor:
Qpex Biopharma, Inc.
Collaborator:
Biomedical Advanced Research and Development Authority